تأثیر تزریق دسفرال وریدی حین تزریق خون در کاهش فریتین سرم در بیماران تالاسمی ماژور

عنوان انگليسی

The impact of intravenous deferoxamine during the blood transfusion on reduction of serum ferritin in thalassemia patients

خلاصه انگلیسی

Introduction: A blood transfusion in patients with thalassemia major is a important treatment base. Iron overload resulted from Long-term transfusion-related using iron chelators particularly by the deferoxamine can be reduced. deferoxamine transfusion is currently conducted at evening (6 nights on a week) and by the pump. Deferral of deferoxamine consumption caused iron overload and its symptoms. Furthermore, applying the other method which is easy to handle and reduce monthly deferoxamine consumption rate is essential. One of these methods which has been mentioned in references is simultaneous blood transfusion and deferoxamine. Methods: This was an experimental study that has been done on 34 thalasemic patiebts refered to Ardabil City hospital. In these patients, intravenous deferoxamine transfused with a three-way connection with blood transfution. The study duration was 6 month and all patients cheked in three and six month after treatment. Results: 15 patients were man (45.7%) and 19% were woman (54.3%). The mean age of Patients was 20.1 with 5.7standard deviation. Results showed that subcutaneous deferoxamine consumption rate and L1 three and six month after simultaneous blood transfusion and intravenous deferoxamine and also average rate of feritine three month after studying proportion to pre-studying had been reduced significantly. But ferritin reduction was not significant statistically six month after due to the arbitrary reduction of subcutaneous deferoxamine consumption and L1. Reduction rate of subcutaneous deferoxamine consumption in patients who had undergone splenectomy was more than other patients. Evaluating the impact of simultaneous intravenous deferoxamine and the blood transfusion in terms of age and gender was not meaningful statistically. Conclution: Simultaneous intravenous deferoxamine and the blood transfusion on thalassemia major cause significantly feritine reduction and subcotaneous deferoxamine consumption and L1 that this method is applicable over patients who have undergone splenectomy. Therefore, It is recommended to use this method.

Document Downloads